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Abstract
Background: Clinical failures singularly targeting amyloid-β pathology indicate a critical need for alternative
Alzheimer’s disease (AD) therapeutic strategies. The mixed pathology reported in a large population of AD patients
demands a multifunctional drug approach. Since activation of cAMP response element binding protein (CREB) plays
a crucial role in synaptic strengthening and memory formation, we retooled a clinical drug with known
neuroprotective and anti-inflammatory activity to activate CREB, and validated this novel multifunctional drug, NMZ,
in 4 different mouse models of AD.
Results: NMZ was tested in three mouse models of familial AD and one model of sporadic AD. In 3 × Tg
hippocampal slices, NMZ restored LTP. In vivo, memory was improved with NMZ in all animal models with robust
cognitive deficits. NMZ treatment lowered neurotoxic forms of Aβ in both APP/PS1 and 3 × Tg transgenic mice
while also restoring neuronal plasticity biomarkers in the 3 × Tg mice. In EFAD mice, incorporation of the major
genetic AD risk factor, hAPOE4, did not mute the beneficial drug effects. In a novel sporadic mouse model that
manifests AD-like pathology caused by accelerated oxidative stress in the absence of any familial AD mutation, oral
administration of NMZ attenuated hallmark AD pathology and restored biomarkers of synaptic and neuronal
function.
Conclusions: The multifunctional approach, embodied by NMZ, was successful in mouse models of AD
incorporating Aβ pathology (APP/PS1), tau pathology (3xTg), and APOE4, the major human genetic risk factor for
AD (EFAD). The efficacy observed in a novel model of sporadic AD (Aldh2−/−) demonstrates that the therapeutic
approach is not limited to rare, familial AD genetic mutations. The multifunctional drug, NMZ, was not designed
directly to target Aβ and tau pathology; however, the attenuation of this hallmark pathology suggests the approach
to be a highly promising, disease-modifying strategy for AD and mixed pathology dementia.
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Background
Alzheimer disease (AD), the most common form of de-
mentia, has reached epidemic proportions, presenting a
severe economic and social burden worldwide. Cur-
rently, no effective therapy exists. Early onset familial
AD (FAD) which represents 1-4 % of cases [1], is linked
to mutations in APP, PS1, and PS2 which increase de-
position of insoluble amyloid-β peptide (Aβ) [2]. Accord-
ing to the Amyloid Hypothesis, Aβ leads to neuronal
death and the second hallmark neuropathology, tau-
containing neurofibrillary tangles (NFT). Consequently,
the search for AD therapeutics has been dominated by
use of transgenic mouse models that overexpress mutant
human genes linked to familial AD. Of AD cases, >96 %
are multifactorial in origin, and importantly, hallmark
AD pathology is often accompanied by other neuropath-
ologic changes. Not unexpectedly, in this substantial
population with AD neuropathology, the correlation of
Aβ histopathology with cognitive decline is poor [3, 4];
providing one possible contributor to the failure of at
least eight therapeutics in late stage clinical trials singu-
larly targeting Aβ [5, 6]. While not dismissing a role for
Aβ in AD pathogenesis, cogent arguments have been
made that a new strategy is needed towards an effective
pharmacotherapeutic response [7–10].
Expert opinion has recognized that AD treatment
must target two or more factors in disease pathogenesis
[8]. Drug repositioning is also attractive with particular
promise shown by anticonvulsants [11]. Zendra (chlo-
methiazole, CMZ), an anticonvulsant with a history of
clinical use, has been shown extensively to be neuropro-
tective against oxidative stress in animal models and tar-
gets inflammation, mitochondrial dysfunction, and
excitotoxicity [12–14]; all of which are proposed to
contribute to AD pathogenesis. CMZ is suggested as a
potential component of future combination therapies
for neuronal injury [14], and we have shown that CMZ
protected primary neurons against oxygen glucose
deprivation (OGD) and neurotoxic oligomeric Aβ
(oAβ) insult [15]. Additional contributors to onset and
progression of AD include early synaptic failure [16],
cerebrovascular impairment [17], and depletion of
neurotrophins [18]. We hypothesized that a small
chemical modification to CMZ, as in the novel thera-
peutic agent, 4-methyl-5-(2-(nitrooxy) ethyl) thiazol-3-
ium chloride (NMZ), would address these contributors
(Fig. 1) [19, 20].
Our approach was inspired by the early work of Lipton
[21] and that of Kandel linking nitric oxide (NO) and
cyclic guanosine monophosphate (cGMP) to cAMP-
response element binding protein (CREB) activation and
long-term potentiation (LTP) [22]. Activation of CREB
by phosphorylation has been shown to be necessary for
memory formation and synaptic strengthening, therefore
we hypothesized that the incorporation of a NO/cGMP
signaling capability in NMZ would restore circuits
dependent on CREB activation essential for learning and
memory [23] (Fig. 1). Recent evidence links decreased
CREB activity and dysregulated CREB-mediated gene
regulation directly to the pathogenesis of AD [24–26].
Therefore NMZ, although not targeted at a specific
component of Aβ accumulation, might reduce brain Aβ
consequent to activation of NO/cGMP/CREB [27, 28].
We previously demonstrated that NMZ retained attributes
of CMZ including potentiation of gamma-aminobutyric
acid (GABA) signaling at the GABAA receptor [19, 20].
We also reported procognitive actions associated with
NO/cGMP, including reversal of scopolamine-induced
cognitive deficits, and demonstrated a high therapeutic
index and efficacy at low nanomolar concentrations of
NMZ in the brain [19].
Testing of NMZ was initiated in a variety of models
demonstrating various subtypes of AD pathology,
achieving a task set by expert opinion, in engagement of
multiple targets in multiple AD transgenic models [8,
29]. First, NMZ was tested in the well-established young
APP/PS1 and older 3 × Tg transgenic mouse models of
FAD. LTP in hippocampal slices was restored by NMZ,
in both APP/PS1 and 3 × Tg mice. Since human apolipo-
protein E4 (APOE4) [30] is the strongest genetic risk fac-
tor for sporadic AD, testing proceeded to the E4FAD
AD mouse model that incorporates targeted replacement
of mouse APOE with hAPOE4. Oxidative stress is a pri-
mary driving force in AD pathogenesis [31, 32], linked
to the lipid peroxidation product 4-hydroxynonenal
(HNE) that accumulates in the brains of late-stage and
presymptomatic AD patients, and is linked to apoE4
negative function [33, 34]. Loss of the enzyme aldehyde
dehydrogenase 2 (ALDH2), which is important for 4-
hydroxynonenal (4-HNE) detoxification, leads to HNE
accumulation, neurodegeneration, and memory loss [35].
Therefore, NMZ was tested in the Aldh2−/− mouse that
develops age-dependent cognitive deficits [36], providing
validation of NMZ in a model of sporadic AD. NMZ, as
a brain-bioavailable small molecule, was observed to
protect against neuronal loss and synaptic dysfunction,
improve memory, lower pro-inflammatory cytokines,
and attenuate hallmark Alzheimer’s pathology in these
multiple mouse models.
Results
NMZ protects primary neurons from oAβ and oxygen
glucose deprivation insult
NMZ retained the neuroprotective actions of CMZ [15],
providing efficacy against OGD (Fig. 2a) and against ex-
posure to oAβ (250nM or 5 μM). Cell viability was re-
duced by ~ 15 % and 60 % after vehicle treatment and
exposure to oAβ, 250nM and 5 μM, respectively (Fig. 2b, c).
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NMZ demonstrated superior protection compared to
CMZ in mitigating oxidative and low and high dose oAβ
insults.
In APP/PS1 mice, NMZ restores cognition and lowers Aβ
NMZ was first tested in APP/PS1 double transgenic
mice that manifest aberrant accumulation of human Aβ
driven by FAD mutations in APP695
K670N/M671Land
PS1M146L. We have previously measured NMZ brain bio-
availability and correlated brain levels with efficacy in
cognition enhancement in scopolamine-induced amnes-
tic mice, demonstrating that the brain concentration of
NMZ required for memory consolidation after amnestic
insult is approximately 0.5–1.0 nM [19]. Our previous
PK/PD studies [19] guided dose selection herein, since
NMZ was effective by both i.p. and p.o. drug administra-
tion at doses of 1 mg/kg and 20 mg/kg/day, respectively.
Therefore, NMZ was administered at 1 mg/kg/day i.p.
and 20 mg/kg/day in drinking water, treating random-
ized groups of both transgenic and age- and sex-
matched wildtype (WT) littermates from 2.5 months of
age for 12 weeks. In the last 2 weeks of treatment, ani-
mals were tested in the radial arm water maze (RAWM).
NMZ treated transgenic animals performed significantly
better than APP/PS1 control animals in trial blocks 2
and 4 (p < 0.05) (Fig. 2d).
In addition to improvement of cognition, whole brain
homogenates were analyzed for various biomarkers. In
whole brain homogenates, a significant reduction of oAβ
was observed for NMZ treated animals for Aβ1–42 spe-
cies (Fig. 2e). Classic Aβ pathology was studied using
quantitative Thioflavin S stereological analysis of serial
coronal sections. NMZ treatment demonstrated almost a
3-fold reduction in Thioflavin S-positive Aβ deposit
Fig. 1 Redesigning of the anticonvulsant Zendra for treatment of AD and dementia. The redesigned small molecule, NMZ, should retain the
reported neuroprotective properties, while additionally targeting synaptic dysfunction, the case for which in AD is persuasive [16]. NMZ was
designed to restore synaptic function via NO/cGMP/CREB signaling, and to retain the beneficial actions of CMZ. The desired activity profile was
observed in multiple animal models on treatment with NMZ. Table indicates a summary of performed assays in used mouse models
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volume in both the cortex and hippocampus (Fig. 2f and
h). Lower levels of inflammatory markers in human
blood and in rat models of hypoxia-ischemia in vivo and
ex vivo, including the pro-inflammatory cytokine tumor
necrosis factor alpha (TNF-α), have been reported previ-
ously for CMZ [12]. Total brain homogenates from
APP/PS1 mice and WT littermates analyzed for TNF-α
showed significant NMZ-induced reduction (Fig. 2e).
This was mirrored by Iba-1 staining of coronal slices
that showed reductions in activated microglia in the
hippocampi and cortex of NMZ treated mice (Fig. 2g).
Thus, in the one FAD model, in which WT mice are lit-
termates, NMZ treatment significantly reduced elevation
of TNF-α; a result compatible with the reported anti-
inflammatory actions of CMZ.
In 3xTg mice, NMZ restores LTP via NO/cGMP, reverses
cognitive deficits, and reduces Aβ and p-tau
The increased age of LaFerla’s 3 × Tg (APP695
K670N/M671L,
PS1M146L, tauP301L) transgenic mouse model at treatment
onset and the more complex pathology represents an in-
creased therapeutic challenge. The effect of NMZ was first
Fig. 2 Retention of neuroprotective activity (a-c) and the effects of NMZ treatment in APP/PS1 mice (d-h). Primary neuronal cultures treated with NMZ
showed neuroprotection when exposed to 2 h OGD (a) and both low (b) and high (c) doses of Aβ oligomers. Data show mean ± S.E.M. normalized to
insult and non-insult vehicle controls. Male APP/PS1 mice (n = 6–8) treated for 12 weeks with NMZ (1 mg/kg, i.p. plus 20 mg/kg/day in drinking water)
demonstrated an improvement in the RAWM task (d) and reduction in levels of the pro-inflammatory marker, TNF-α, and in neurotoxic oAβ, in whole
brain homogenates (e). Data show mean ± S.E.M compared to vehicle. NMZ also reduced total Aβ1–42 deposit volumes compared to vehicle control in
cortex and hippocampal homogenates (f). Data show mean ± S.E.M of total deposit volume determined by fluorescent staining and were analyzed by
two-tailed student’s t-test. All statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001. Representative images of hippocampi and cortices
with histochemical staining reveal significantly less activated microglia shown with Iba-1 (magnification: 4×, 10×, and 20× from left to right) (g) and
reduced thioflavin-S staining of amyloid plaques in NMZ treatment compared to vehicle (magnification: 2× and 6×) (h)
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studied in LTP in the CA3-CA1 pathway in hippocampal
slices from 16-month-old male mice [37]. Since the 3 × Tg
is a homozygous line, the 129/SvJ x C57BL/6 background
was used as an outbred line to provide control slices to
give baseline performance. NMZ treatment resulted in a
significant increase in fEPSP after LTP induction com-
pared to untreated transgenics, to levels similar to WT
control (Fig. 3a). To investigate the involvement of the
Fig. 3 NMZ treated 3xTg mice show improvements in LTP, behavior, synaptic biomarkers, and Aβ pathology. LTP was measured in the CA1
region of hippocampal sections from 16 month male 3 × Tg mice (n = 9-12) or in littermate controls treated with NMZ (50 μM) and ODQ (10 μM)
30 min prior to TBS and continued throughout. Fifty min after LTP induction, NMZ showed restoration of LTP deficits to WT levels, while ODQ
completely blocked this activity (a). Analysis of theta bursts showed an increase by NMZ during induction of long-term potentiation (b). Data
show mean ± S.E.M. normalized to baseline. Male and female 3xTg mice (n = 8–12) treated for 10 weeks with NMZ (1 mg/kg, i.p. + 20 mg/kg/day
p.o) showed reversal of memory deficits to levels observed in WT mice in the STPA task 24 h after training (c). NMZ treatment resulted in an
elevation of biomarkers associated with synaptic and neuronal plasticity (pCREB and BDNF) in whole brain homogenates measured by ELISA
however not changing the total amount of total CREB measured by western blot (d and e). NMZ treatment attenuated insoluble and oligomeric
Aβ (f) and total tau (g), both markers of AD hallmark pathology, in whole brain homogenates. Data show mean ± S.E.M. compared to vehicle
control. Statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001 and were analyzed by unpaired student’s t-test. NMZ treatment
showed a decrease in Aβ staining in the CA1 region of the hippocampus in treated animals but a negligible effect on the cortex. Representative
images are shown with thioflavin-S (magnification 4×) staining and 6E10 antibody in the hippocampus (magnification 4×) and subiculum (magnification
10×) (h). AT8 immunohistochemistry in hippocampus and cortex (magnification 6× and 20×) showed a decrease in phosphorylated tau in the NMZ
treated compared to the vehicle (i)
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NO/cGMP pathway in the action of NMZ, ODQ (1H-[1,
2, 4] oxadiazolo-[4, 3-a] quinoxalin-1-one), a selective in-
hibitor of soluble guanylyl cyclase (sGC) was used to block
cGMP production, and added 30 min prior to induction.
LTP induced in the presence of both NMZ and ODQ was
not significantly different to that obtained in untreated
3 × Tg slices. Examination of the field responses during
theta-burst stimulation (TBS) indicated that NMZ facili-
tated LTP in 3 × Tg mice by enhancing the depolarization
induced by the high frequency bursts (Fig. 3b); this effect
was also attenuated by inhibition of cGMP production by
ODQ.
In light of the findings in APP/PS1 mice, we chose to
use a similar treatment protocol in 3 × Tg mice. Drug
treatment started at 10 months of age for females and
12 months of age for males (to account for early path-
ology in females). In the last week of the trial, the ani-
mals were tested in the step through passive avoidance
(STPA) task. The performance of NMZ treated 3 × Tg
mice was comparable to untreated WT and significantly
better than vehicle treated 3xTg mice (Fig. 3c). The pro-
cognitive activity of NMZ is proposed to be mediated
via re-activation of CREB, leading to increased expres-
sion of gene products, notably brain-derived neuro-
trophic factor (BDNF). In cerebral homogenates, both
pCREB and BDNF levels were significantly increased in
NMZ treated 3 × Tg mice (Fig. 3d and e). Aβ1–42 mea-
sured in the insoluble guanidine extracted fraction and
oAβ in the soluble fraction was lowered with NMZ
treatment (Fig. 3f ). Staining using the Aβ antibody 6E10
revealed fewer β-amyloid plaques in the hippocampal
formation, particularly in the subiculum (Fig. 3h), al-
though the cortex did not show a significant difference
in plaque pathology. Immunohistochemical analysis
using AT8 an antibody directed against phosphorylated
tau showed a significant decrease in staining in the CA1
region of NMZ treated mouse brains (Fig. 3i). In con-
trast, total tau was unchanged, measured by western blot
of total brain extract using antibody HT7 (a human-
specific monoclonal antibody recognizing amino acids
159–163) (Fig. 3g).
In EFAD mice, NMZ lowers Aβ and elevates CREB
phosphorylation and PSD-95
E4FAD mice carry targeted replacement of mouse APOE
with human APOE4. The 5 × FAD background causes
deposition of human Aβ, which is more severe in apoE4
carrier mice than in mice carrying the apoE2 or apoE3
isoforms [30]. The E4FAD mouse is therefore an import-
ant AD model for drug testing of predictive efficacy in
the human apoE4 carrier population. Male E4FAD mice
at 3.5 months of age were, as in the previous mouse
models, administered NMZ i.p. (1 mg/kg/day) and p.o.
in hydrogel (20 mg/kg/day) for 12 weeks before sacrifice,
allowing comparison with published studies on male EFAD
mice at the same age [38]. A significant cognitive deficit
was not observed using the STPA task, nor nesting behav-
ior assessment up to 6 months of age, compared to C57BL/
6 WT mice. However, after tissue extraction, Aβ1–42
showed a significant reduction in the soluble, insoluble and
oligomeric forms (Fig. 4a, b). Levels of pCREB and total
CREB, measured in hippocampal homogenates, showed a
significant increase in pCREB and no significant differences
in total CREB in the NMZ treatment group (Fig. 4c). Acti-
vation of CREB is intrinsically linked to synaptic function;
and the scaffold protein, postsynaptic density protein 95
Fig. 4 NMZ treated E4FAD mice show improvements in Aβ pathology and synaptic biomarkers. Male E4FAD (n = 8–12) mice treated with NMZ
for 12 weeks (1 mg/kg, i.p. + 20 mg/kg/day p.o.) showed attenuated formation of insoluble and soluble Aβ1–42 (a) and oligomeric Aβ (b) in
hippocampal homogenates measured by ELISA. NMZ treatment led to elevated pCREB in the hippocampal fraction (c) without a change in total
CREB determined by western blot. NMZ treated mice restored levels of the synaptic marker PSD-95 determined by western blot (d). Data show
mean ± S.E.M. compared to the vehicle control. Statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001 and were analyzed by
unpaired student’s t-test
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(PSD-95), plays a critical role in synaptic plasticity and
synaptic dysfunction in AD [39, 40]. Immunoassay of ho-
mogenates from E4FAD mice showed a significant in-
crease of PSD-95 in the hippocampus of E4FAD mic3
after treatment with NMZ (Fig. 4d).
In Aldh2 −/− mice, NMZ restores synaptic plasticity and
attenuates AD hallmark pathology
Aldh2−/− mice, compared to age and sex-matched litter-
mates, show a progressive decrease in performance, begin-
ning at 2.5–3 months of age, in both the novel object
recognition (NOR) and Y-maze tasks, measures of non-
spatial and spatial working memory [36]. Given the posi-
tive outcomes of NMZ treatment in the three familial AD
transgenic mouse models, we decided to forego i.p. deliv-
ery in Aldh2−/− mice, administering drug solely by the oral
route (20 mg/kg/day) for 12 weeks from 3 months of age.
The Aldh2−/− mouse represents a model for accelerated
aging manifested by accumulation of lipid peroxidation
products that fail to be cleared by Aldh2 enzyme action
and pathology reflected by significantly increased levels of
HNE-adducted proteins. We hypothesized that NMZ
would counteract the downstream effects of this pathology
on neuronal and synaptic function without impacting up-
stream HNE-adduct formation. Marked increases in HNE
adduct formation occur early in Aldh2−/− mouse brains,
characterized by increases in both the density and number
of immunoreactive bands in immunoblots, which was not
significantly perturbed by administration of NMZ (Fig. 5a).
Aldh2−/− mice demonstrated age-related increases in sol-
uble Aβ and phospho-tau that were significant at 6 months
of age [36] and attenuated by NMZ treatment (Fig. 5b, c),
without change in total tau. Age-related changes in synap-
tic and neuronal markers were also significantly attenu-
ated by NMZ treatment (Fig. 5d), as were age-related
increases in activated caspases 3 and 6 (Fig. 5e). These
progressive biochemical changes linked to synaptic and
neuronal dysfunction are intrinsically linked with AD in
humans.
Aldh2−/− and WT mice were tested in the Y-maze and
NOR before randomization into treatment groups. In
both tasks, untreated Aldh2−/− mice showed a significant
cognitive deficit that was more distinct with age; NMZ
treatment having no effect on WT mice. A significant
deficit was seen in Aldh2−/− mice prior to randomization;
whereas, NMZ treated mice up to 6 months of age
showed no cognitive deficit in the Y-maze and NOR
(Fig. 6a, b).
A final ex vivo experiment was carried out using the
acetylcholine receptor agonist, carbachol, applied to hip-
pocampal slices from NMZ-treated Aldh2−/− mice, WT
littermates, and their vehicle controls. Carbachol stimu-
lation of hippocampal slices from 6 month old WT mice
that had been administered NMZ or vehicle control for
12 weeks caused significant and similar elevation of
pCREB (Fig. 6c). Slices from vehicle treated Aldh2−/−
mice showed significantly attenuated basal pCREB re-
sponse relative to WT and no significant effect of carba-
chol stimulation, whereas hippocampi from Aldh2−/−
mice that had undergone NMZ treatment showed basal
response and stimulation in response to carbachol com-
parable to WT littermates. NMZ treatment of Aldh2−/−
mice was able to restore normal basal and stimulated
pCREB signaling.
Discussion
The collected data presented herein profile an orally bio-
available small molecule, NMZ, that yields beneficial
biochemical and functional outcomes in four diverse
mouse models of Alzheimer’s disease, building on animal
data showing the ability of NMZ to restore memory
consolidation in response to a variety of acute amnestic
insults and in response to saporin-induced cholinergic
lesions [19, 41]. Lowering brain Aβ levels has remained
the primary and often exclusive target for therapeutic
intervention in AD; however, the failure of such thera-
peutic agents to reach primary endpoints in phase 3
clinical trials, emphasizes the urgent need for new ap-
proaches. Nevertheless, any new therapeutic approach to
AD should also positively impact hallmark neuropathol-
ogy. NMZ targets multiple contributing mechanisms in
AD and dementia. Beginning with the APP/PS1 mouse
that manifests Aβ pathology and cognitive deficits, the
efficacy of this approach was demonstrated. Adding tau
pathology in older 3 × Tg mice and hAPOE4 in E4FAD
mice did not blunt the efficacy of NMZ, which was also
demonstrated in a novel mouse model of sporadic AD.
AD accounts for up to 80 % of dementia and half of
those diagnosed with dementia have more than one
pathology; for example vascular dementia, and dementia
with Lewy bodies. However, in the population with AD
pathology, Aβ histopathology with cognitive deficits have
shown to be poorly correlated [3, 4], and Aβ-specific
therapeutics might be expected to fail in this clinical
population. AD is a multifactorial disease linked to other
aging-associated maladies and to factors common to
other neurodegenerative diseases, for example, glutam-
ate excitotoxicity, oxidative stress, and inflammation
[42]. Neuroprotective agents have been targeted to these
and other contributors to neurodegeneration. For ex-
ample, the clinical anticonvulsant Zendra/CMZ, was
repurposed in Phase 3 clinical trials as a neuroprotective
drug for use in spinal cord injury and ischemic stroke.
CMZ, clinically prescribed for anxiety and agitation in
the elderly, continues to be recommended as a compo-
nent of combination therapy for stroke and neuronal
injury [14]. GABA-potentiation [43] and TNF-α antag-
onism [44, 45] have been targeted for AD therapy and
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Fig. 5 (See legend on next page.)
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there is evidence that CMZ provides these attributes in
addition to attenuation of mitochondrial and neuronal
damage [12]. The early loss of synaptic function in both
AD and mild cognitive impairment (MCI), which corre-
lates with cognitive dysfunction and memory loss [46, 47],
must be addressed; therefore CMZ, was chemically modi-
fied in the form of NMZ, to treat Alzheimer’s and demen-
tia [20] (Fig. 1). Importantly, NMZ was shown to retain
the beneficial properties of CMZ [19].
Studies suggest that restoration of synaptic failure in
AD can be achieved through CREB activation [48], and
since CREB activation is coupled to NO/cGMP signaling
in the hippocampus [22, 23], we hypothesized that in-
corporation of a CREB activating moiety would reacti-
vate circuits associated with CREB which are vital to
learning and memory [49]. NMZ was designed to acti-
vate CREB through the NO/cGMP signaling pathway
[19], regulating the strength of synaptic transmission in
an activity-dependent manner in the hippocampus [50]
(Fig. 1). NMZ was effective in 3 × Tg mice, wherein LTP
restoration was shown to be cGMP dependent (Fig. 3).
NMZ significantly restored cognitive function in differ-
ent memory tasks in 6 month old APP/PS1 and 12–15
month old 3 × Tg mice (Figs. 2 and 3). Given this positive
response in FAD mice to NMZ administered using daily
i.p. delivery supplemented by oral delivery over 12 weeks,
administration of NMZ to Aldh2−/− mice was reduced to
oral delivery alone. Working memory was measured in
two further memory tasks (Fig. 6), showing a progressive
decline in performance in Aldh2−/− mice compared to the
WT littermate control group. Before randomization for
drug treatment at 2.5–3 months, Aldh2−/− mice showed a
deficit in both tasks. After 4 weeks treatment with NMZ,
spontaneous alternation in the Y-maze was not different
from that of WT controls; and after 8 weeks treatment,
NOR performance recovered to that of WT controls.
Thus, in 4 different behavioral assays of working and
spatial memory and 3 different animal models, NMZ ad-
ministration rescued the age-related decline in learning
and memory.
Molecular network analysis and other clinical evidence
converges on aberrant CREB-mediated gene regulation
in the AD hippocampus [25, 26], compatible with the
role of CREB phosphorylation in mediating synaptic
plasticity through structural changes at synapses. In
NMZ-treated 3×Tg, E4FAD, and Aldh2−/− mice, levels of
pCREB in either whole brain homogenates or hippo-
campi were significantly increased over vehicle control
(Figs. 2, 3, 4 and 5). CREB acts upon downstream genes
involved in synaptic and neuronal plasticity and neuro-
genesis, including BDNF. NMZ caused elevation of
BDNF and of the protein biomarker of synaptic function,
PSD-95 (Figs. 3, 4 and 5). The inability of CREB, in hip-
pocampal slices from Aldh2−/− mice, to respond to cho-
linergic stimulation further mirrors the loss of function
of CREB in AD (Fig. 6). Given the evidence for direct
dysregulation of CREB by oAβ and reciprocal regulation
of amyloidogenesis by CREB [27, 28, 51], an agent that
elevates pCREB and biomarkers of synaptic function in
the AD brain may have a reciprocal and beneficial effect
on production and/or clearance of Aβ. More direct links
between NO/cGMP signaling and APP processing via
beta-secretase-1 (BACE1) have been reported: the anti-
amyloidogenic activity of an NO-donor was reported to
be BACE1 and cGMP-dependent [52, 53], and intact
endothelial NO synthase (eNOS) activity in the cerebral
microvasculature [54] and brain tissues is linked with
downregulation of BACE1 activity [52, 55, 56]. In three
models of FAD, treatment with NMZ resulted in attenu-
ated levels of Aβ (Figs. 2, 3, 4, 5 and 6).
Contemporary disease-modifying approaches to AD
remain targeted at lowering brain Aβ aggregates, includ-
ing immune-based approaches. Most recently the gante-
nerumab Aβ antibody was shown preferentially to bind
aggregated brain Aβ and in APP/PS-1 mice, to reduce or
halt Aβ plaque formation [57]; however, the Phase 3
clinical trial, in early stage symptomatic patients with
evidence of amyloid, was halted in December 2014.
Since AD is defined by the hallmark neuropathologies of
aberrant Aβ and tau protein aggregates, any new
disease-modifying therapy should attenuate these path-
ologies. The data presented herein for NMZ in 4 pre-
clinical animal models suggest that therapeutic strategies
targeting synaptic and neuronal dysfunction are also able
to ameliorate hallmark pathology. NMZ treatment was
shown to lower p-tau in the 3 × Tg mouse using anti-
bodies that selectively recognize neurofibrillary filaments
made up of hyperphosphorylated human tau and also to
attenuate native p-tau formation in the Aldh2−/− mouse
(Figs. 3 and 5).
(See figure on previous page.)
Fig. 5 NMZ treated Aldh2−/− mice show improvements in AD-like pathology, synaptic biomarkers and neuronal function. Hippocampal
homogenates (30 μg protein) from Aldh2−/− mice, treated with NMZ or vehicle for 12 weeks, showed no effect of NMZ on HNE adduct
formation by dot-blot immunoassay of HNE protein adducts; whereas HNE adducts were significantly elevated relative to treated and untreated WT
mice mice (a). Immunoblot analysis of hippocampal homogenates of WT and drug or vehicle treated Aldh2−/− mice quantitated by densitometry with
representative blots shown: monomeric Aβ (b) and p-tau (c); synaptic biomarkers PSD-95 and synaptophysin (d); and activated caspases (e). Data are
presented as the mean ± S.D. and were analyzed by one-way ANOVA with Bonferroni post-hoc tests. Statistical significance is indicated by *p < 0.05,
**p < 0.01, ***p < 0.001 compared with wildtype; †, significant difference from Aldh2−/− (†† p < 0.01, ††† p < 0.001)
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Fig. 6 (See legend on next page.)
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Conclusions
Disease-modifying approaches to AD remain predomin-
antly targeted at lowering Aβ aggregates in the brain.
The development of effective therapies for AD and
mixed pathology dementia has been limited by the lack
of suitable animal models adequately reflecting the com-
plexity of human AD. We successfully modified a neuro-
protective, anti-inflammatory drug to retain these
functions and to address synaptic dysfunction in AD: the
new orally bioavailable small molecule was effective in
three FAD models of increasing therapeutic challenge
and in a new animal model of AD not linked to rare
genetic mutations. The multifunctional approach incorpo-
rates NO/cGMP signaling which regulates the strength of
synaptic transmission in an activity-dependent manner in
the hippocampus [50]. Importantly, NMZ reactivated
CREB signaling, effectively restored LTP, improved learn-
ing and memory, and attenuated TNFα and pathological
hallmarks of AD. These observations should encourage al-
ternate, parallel strategies to the singular targeting of Aβ.
The increasing recognition that AD and age-related de-
mentia may have underlying mixed pathology further sup-




All animal care and procedures were conducted with ap-
proved institutional animal care protocols at UIC
(OACIB), Columbia University (IACUC) and Queen’s
University (UACC), in accordance with the NIH Guide
for the Care and use of Laboratory Animals.
Mice were randomly grouped into NMZ or vehicle
treatment groups and mice were treated with drug or
vehicle for 10–12 weeks; where applicable littermates
were sex and age-matched. APP/PS1 mice (6–8 weeks)
were administered drug (1 mg/kg qd) or saline i.p. sup-
plemented with drug (20 mg/kg qd in drinking water).
3 × Tg mice (males 12 months; females 10 months) and
E4FAD mice (male 4 months) were administered drug
using the same protocol, with the exception that drug in
hydrogel replaced drinking water [38]. Aldh2−/− mice
(3 months) were treated with drug (20 mg/kg qd) in
hydrogel. Primary cultures of cortical neurons were pre-
pared from DIV 16 days old rat embryos and subjected
to transient OGD or oAβ insults as described [15].
Electrophysiology
LTP measurements were made on 400 μm 3 × Tg mouse
slices from 16-month-old male mice using ten theta
bursts. Slices were perfused with ODQ (10 μM) and/or
NMZ (50 μM) in aCSF perfusate for 30 min before indu-
cing LTP as measured by fEPSP slope measured for
50 min.
Behavior
The RAWM task has proven informative in the analysis
of short-term spatial working memory in AD models
and was performed as previously described [58]. NOR
and Y-maze were performed as described: preliminary
data, tested using a three-way analysis of variance,
showed no sex differences in either task for Aldh2−/−
mice, therefore NOR and Y-maze data from male and fe-
male mice were combined for analysis [36]. In the NOR,
on the test day, animals were allowed to explore the ob-
jects until they accumulated a total of 30 s of exploration
time, and the discrimination index (difference in time
exploring the novel and familiar object, divided by total
exploration time) determined. In the Y-maze, spontan-
eous alternation rate was calculated as the total triads
containing entries into each of the three arms without
repeated entry into a previously visited arm, divided by
the total number of arm entries. STPA has been widely
used to test long-term working memory and was per-
formed as previously described [20].
Biomarkers and immunohistochemistry
Brains were separated by hemisphere for immunohisto-
chemistry or ELISA/immunoblot studies. Frozen hemi-
brains were homogenized and serially extracted for
biomarker measurement. For EFAD mice, proteins
were extracted from the hippocampus using a three
step serial extraction as described [38]. Levels of oAβ
(Biosensis) Aβ42 (Invitrogen), TNF-α (Invitrogen),
(See figure on previous page.)
Fig. 6 NMZ-treated Aldh2−/− mice show rescued learning, memory and CREB responsiveness in carbachol treated hippocampal slices.
Reversal of the age-dependent decline in the spontaneous alternation rate and discrimination index in the Y-maze task (a) and NOR
task (b), respectively, was observed in male and female Aldh2−/− mice: after obtaining baseline measurements at 2.5–3 months, mice
were randomized to drug or vehicle control groups (n = 8–11) and treated with NMZ (20/mg/kg/day p.o.) or vehicle at 3 months of age
for a period of 12 weeks. Pre-randomization data were compared by an unpaired t-test and post-randomization groups by a one-way
ANOVA with a Bonferroni post-hoc test. Hippocampal slices from 6 month old wild type and Aldh2−/− mice that had been treated with
NMZ or vehicle control for 12 weeks, were incubated with 50 μM carbachol or vehicle (Basal) for 30 mins and snap frozen. Immunoblot
analysis for pCREB was performed using 30 μg protein of hippocampal homogenate, and immunoreactive bands were quantitated by
densitometry (c). Data are presented as the mean ± S.D. (n = 3) and were analyzed by a one-way ANOVA with a Bonferroni post-hoc
test: * significant differences from basal (** p < 0.01, ***p < 0.001); ψ significant difference compared to basal in all other
groups (p < 0.05)
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pCREB (Biosource), and BDNF (Promega) were deter-
mined for soluble and insoluble fractions using sand-
wich ELISA kits and reported as weight/unit per
milligram of soluble protein. Samples for immunoblot
analysis of Aβ were incubated in Laemmli buffer con-
taining 6 M urea for 30 min prior to electrophoresis.
The following antibodies were used: mouse monoclo-
nal to Aβ (W0-2, Millipore, recognizes residues 4–10
of Aβ), rabbit polyclonal antibody to 4-hydroxynonenal
(HNE11-S antibody, Alpha Diagnostics International),
mouse monoclonal antibody to PHF-tau (AT8 antibody,
Pierce Thermo Scientific), rabbit polyclonal antibody to
caspase-3 (ab90437, Abcam), rabbit polyclonal antibody to
caspase-6 (ab52295, Abcam), mouse monoclonal antibody
to PSD-95 (Pierce Thermo Scientific), mouse monoclonal
antibody to total tau (ab64193, Abcam), rabbit polyclonal
antibody to phospho-CREB (Ser 133, 06–519, Upstate
Biotechnology), rabbit polyclonal antibody to total CREB
(06–863, Millipore), mouse monoclonal antibody to β-
actin (Sigma). Serial coronal brain sections (30 μm) of
paraformaldehyde-fixed hemi-brains were cut frozen using
a Leica cryostat in six adjacent series and immunohisto-
chemically processed using antibodies directed against
Aβ/APP, a phospho-specific (Ser202/Thr205) tau anti-
body, and microglia marker Iba1 (primary, 6E10, Covance,
1:2000; AT8, ThermoFisher, 1:1000; anti-Iba-1, Wako,
1:1000; secondary goat anti-mouse IgG for 6E10/AT8,
1:200; goat anti-mouse IgM for anti-Iba-1, 1:200). Quanti-
tative Thioflavine-S staining was performed on frozen
hemi-brain 20 μm serial slides. Aβ deposition stereology
in cortex and hippocampus were analyzed using quantita-
tive Metamorph software. Brain slices, were incubated
with carbachol or vehicle (Basal) for 30 mins and snap fro-
zen. Immunoblot analysis for pCREB was performed using
30 μg protein of hippocampal homogenate, and immuno-
reactive bands were quantitated by densitometry. Hippo-
campal slices from WT and Aldh2−/− mice that had been
treated with NMZ or vehicle control for 12 weeks, were
incubated with carbachol (50 μM) or vehicle for 30 min
and snap frozen, before immunoblot analysis of pCREB in
homogenates.
Statistical analysis
Unless otherwise stated, all data are expressed as mean ±
SD or SEM and were analyzed by one-, two- or three-way
analysis of variance with either Bonferroni’s or Tukey’s
post-hoc test, and/or a Student’s t test for unpaired data.
A p-value of 0.05 or less was considered statistically sig-
nificant. All statistical analysis was done of GraphPad
Prism.
Ethical committees
The Office of Animal Care and Institutional Biosafety
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